Skip to main content
. 2020 Jul 30;5:70. doi: 10.1038/s41541-020-00218-y

Fig. 6. Protective efficacy by dual MVA-GnGc-NS1 immunization after challenge with RVFV.

Fig. 6

Balb/C mice were inoculated with MVA-wt or MVA-GnGc-NS1, and then infected with 500 PFU of RVFV at day 35. a Level of neutralizing antibodies against RVFV at 14 d.p.v. b Viremia at 3 d.p.i. measured by plaque assay on Vero cells and expressed as PFU/ml. Horizontal lines indicate mean. Statistical differences were calculated by Mann–Whitney nonparametric tests. c Survival rates of vaccinated and non-vaccinated mice after challenge; *p ≤ 0.05.